In a recent study published in Science Immunology, researchers investigated the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant of concern (VOC) Omicron's immune escape mechanisms ...
New in vitro neutralization data show continued, consistent neutralizing activity of PEMGARDA™ (pemivibart) against XEC Centers for Disease Control reports XEC and KP.3.1.1 (previously disclosed as ...
Invivyd, Inc. has announced new in vitro data showing that its monoclonal antibody PEMGARDA™ (pemivibart) maintains effective neutralizing activity against the prevalent LP.8.1 variant of SARS-CoV-2, ...
On Friday, Invivyd Inc. (NASDAQ:IVVD) announced that new in vitro neutralization data show continued neutralizing activity of Pemgarda (pemivibart) and pipeline candidate VYD2311 against dominant SARS ...
In a recent study posted to the medRxiv* preprint server, researchers evaluated the neutralizing ability of sera from coronavirus disease 2019 (COVID-19) patients. Study: Pre-Omicron vaccine ...
According to more recent data, it has been determined that Pemgarda is likely to retain adequate neutralization activity against KP.3.1.1. The Food and Drug Administration (FDA) has updated the Fact ...
The FDA has determined that the monoclonal antibody pemivibart (Pemgarda) is likely to be effective against currently circulating SARS-CoV-2 variants, including KP.3.1.1 and LB.1. "Based on current ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback